MX2023010412A - Composiciones y metodos para direccion a celulas inflamatorias o activadas y tratamiento o aminoracion de condiciones inflamatorias y dolor. - Google Patents

Composiciones y metodos para direccion a celulas inflamatorias o activadas y tratamiento o aminoracion de condiciones inflamatorias y dolor.

Info

Publication number
MX2023010412A
MX2023010412A MX2023010412A MX2023010412A MX2023010412A MX 2023010412 A MX2023010412 A MX 2023010412A MX 2023010412 A MX2023010412 A MX 2023010412A MX 2023010412 A MX2023010412 A MX 2023010412A MX 2023010412 A MX2023010412 A MX 2023010412A
Authority
MX
Mexico
Prior art keywords
pain
methods
inflammation
disease
inflammatory
Prior art date
Application number
MX2023010412A
Other languages
English (en)
Spanish (es)
Inventor
Yury Miller
Soo- Ho CHOI
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2023010412A publication Critical patent/MX2023010412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/99—Racemaces and epimerases (5.1) acting on other compounds (5.1.99)
    • C12Y501/99006—NAD(P)H-hydrate epimerase (5.1.99.6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023010412A 2021-03-18 2022-03-18 Composiciones y metodos para direccion a celulas inflamatorias o activadas y tratamiento o aminoracion de condiciones inflamatorias y dolor. MX2023010412A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163162714P 2021-03-18 2021-03-18
PCT/US2022/020991 WO2022198073A1 (en) 2021-03-18 2022-03-18 Compositions and methods for targeting inflammatory or arctivated cells and treating or ameliorating inflammatory conditions and pain

Publications (1)

Publication Number Publication Date
MX2023010412A true MX2023010412A (es) 2024-01-25

Family

ID=83321214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010412A MX2023010412A (es) 2021-03-18 2022-03-18 Composiciones y metodos para direccion a celulas inflamatorias o activadas y tratamiento o aminoracion de condiciones inflamatorias y dolor.

Country Status (10)

Country Link
US (1) US20240209341A1 (https=)
EP (1) EP4308233A4 (https=)
JP (1) JP2024510757A (https=)
KR (1) KR20230159847A (https=)
CN (1) CN117083381A (https=)
AU (1) AU2022238450A1 (https=)
CA (1) CA3212101A1 (https=)
IL (1) IL305955A (https=)
MX (1) MX2023010412A (https=)
WO (1) WO2022198073A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4203987A4 (en) * 2020-08-25 2024-10-16 The Regents of The University of California COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR NEUROINFLAMMATION
WO2025076208A1 (en) * 2023-10-03 2025-04-10 Raft Pharmaceuticals, Inc. Compositions and methods for treating pain disorders
WO2026006723A1 (en) * 2024-06-27 2026-01-02 Anand Rene Reagents and methods for treating headache and migraine pain and co-morbidities thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8513702D0 (en) 1985-05-30 1985-07-03 Gill S S Expansible trocar
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20030181366A1 (en) * 2002-03-21 2003-09-25 Yan Luo Peptide inhibitors of Akt and uses thereof
US7343205B1 (en) 2002-08-20 2008-03-11 Boston Scientific Neuromodulation Corp. System and method for insertion of a device into the brain
ES2581781T3 (es) 2002-09-24 2016-09-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Método por imágenes para administración mejorada por convección de agentes terapéuticos
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
WO2006044986A1 (en) 2004-10-18 2006-04-27 Nitto Denko Corporation Intracellular peptide delivery
US20060129126A1 (en) 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
WO2008067183A1 (en) 2006-11-30 2008-06-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education A device for cell delivery into the brain or body
WO2008070769A1 (en) 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
US10364275B2 (en) * 2013-05-27 2019-07-30 The Regents Of The University Of California Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)
ES2883417T3 (es) * 2015-12-10 2021-12-07 Univ California Composiciones para su uso en el tratamiento o mejora de neuroinflamación, neurodegeneración, dolor neuropático y migraña

Also Published As

Publication number Publication date
CA3212101A1 (en) 2022-09-22
AU2022238450A9 (en) 2023-11-16
CN117083381A (zh) 2023-11-17
EP4308233A4 (en) 2025-08-13
EP4308233A1 (en) 2024-01-24
IL305955A (en) 2023-11-01
AU2022238450A1 (en) 2023-11-02
KR20230159847A (ko) 2023-11-22
WO2022198073A1 (en) 2022-09-22
JP2024510757A (ja) 2024-03-11
US20240209341A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
MX2023010412A (es) Composiciones y metodos para direccion a celulas inflamatorias o activadas y tratamiento o aminoracion de condiciones inflamatorias y dolor.
US20230374547A1 (en) Cns gene delivery using peripheral administration of aav vectors
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
MX2022013963A (es) Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
MX2021001292A (es) Metodos para la modificacion genica de celulas hematopoyeticas.
EP2809780A1 (en) Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
CO2023009633A2 (es) Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal
Arakawa et al. iPSC-derived mesenchymal stem cells attenuate cerebral ischemia-reperfusion injury by inhibiting inflammatory signaling and oxidative stress
WO2020219766A8 (en) Compositions useful in treatment of rett syndrome
EP4453233A1 (en) Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections
CL2024000062A1 (es) Composición farmacéutica de virus no encapsulado
MX2020002148A (es) Vectores adenoasociados recombinantes.
WO2023004407A3 (en) Adeno-associated virus compositions and methods of use thereof
WO2023069967A8 (en) Compositions useful in treatment of cdkl5 deficiency disorder (cdd)
MX2025000757A (es) Casetes reguladores específicos del músculo
MX2025001446A (es) Vector viral
CA3183395A1 (en) Endothelial cells for mitigation of chemotherapy-induced toxicity
WO2024126762A3 (en) Recombinant adeno-associated virus gene therapy vectors with reduced liver tropism and enhanced transduction of cardiac cells for the therapy of heart diseases and diseases associated with heart dysfunction
CL2024000481A1 (es) Proteína de la cápside vp1 modificada aislada de aav9
ZA202306485B (en) Peptides for the treatment of respiratory infections of viral origin
PE20242364A1 (es) Proteinas actrii y usos de las mismas
ZA202504716B (en) Pharmaceutical composition of non-enveloped virus
Yuhnev et al. Search of novel antimicrobial peptides of the cathelicidins and defensins families in moose (Alces alces) leucocytes
Zhang et al. A novel antiviral peptide Laby A1/A3 precursor-SUMO against PCV2 replication with broad-spectrum antiviral potential
AR123698A1 (es) Formulaciones para administración supracoroidal tales como formulaciones con formación de agregados